# An EEG Study of Intravenous Ketamine for Major Depression Disorder

> **NCT05506462** · PHASE4 · UNKNOWN · sponsor: **Ehave Inc.** · enrollment: 35 (estimated)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Ketamine Hydrochloride

## Key facts

- **NCT ID:** NCT05506462
- **Lead sponsor:** Ehave Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01
- **Primary completion:** 2024-01
- **Final completion:** 2024-02
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2022-08-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05506462

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05506462, "An EEG Study of Intravenous Ketamine for Major Depression Disorder". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05506462. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*